Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
Drug approved for patients with ALK-positive, early-stage cancer who undergo surgery to remove their tumor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.